FRI0161 a phase 1B/2A study of the safety, tolerability, pharmacokinetics and pharmacodynamics of XMAB® 5871 in patients with rheumatoid arthritis
M Jaraczewska-Baumann, M Korkosz, G Sulyok… - Annals of the Rheumatic …, 2015 - Elsevier
Background XmAb® 5871 is a humanized Fc engineered monoclonal antibody (mAb) that
binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to the
inhibitory Fcγ receptor IIb (FcγRIIb). Co-ligation of CD19 and FcγRIIb by XmAb5871 has
been demonstrated to reversibly down-regulate B cell activity. XmAb5871 is being
developed for the treatment of B cell mediated autoimmune disorders. Objectives The
primary objective was to determine the safety, tolerability, PK, PD and immunogenicity …
binds to the B cell restricted surface antigen CD19 and has enhanced Fc binding to the
inhibitory Fcγ receptor IIb (FcγRIIb). Co-ligation of CD19 and FcγRIIb by XmAb5871 has
been demonstrated to reversibly down-regulate B cell activity. XmAb5871 is being
developed for the treatment of B cell mediated autoimmune disorders. Objectives The
primary objective was to determine the safety, tolerability, PK, PD and immunogenicity …